Measurement of Proteasome Activity in Peripheral Blood Mononuclear Cells as an Indicator of Susceptibility to Bortezomib-Induced Severe Neurological Adverse Events in Patients with Multiple Myeloma

Publisher： Karger

E-ISSN： 1421-9662|134|1|25-31

ISSN： 0001-5792

Source： Acta Haematologica, Vol.134, Iss.1, 2015-04, pp. : 25-31

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bortezomib-Induced Rhabdomyolysis in Multiple Myeloma

By  

Acta Haematologica, Vol. 116, Iss. 3, 2006-10 ,pp. : 203-206

Karger

Access to resources Recommend Favorite

Treatment of Multiple Myeloma: Thalidomide-, Bortezomib-, and Lenalidomide-Induced Peripheral Neuropathy

By  

Oncology Research and Treatment, Vol. 37, Iss. 9, 2014-08 ,pp. : 506-513

Karger

Access to resources Recommend Favorite

Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs

By          

International Journal of Molecular Medicine, Vol. 29, Iss. 1, 2012-01 ,pp. : 102-106

Spandidos Publications

Access to resources Recommend Favorite

The effects of bortezomib on bone disease in patients with multiple myeloma

By  

CANCER, Vol. 120, Iss. 5, 2014-03 ,pp. : 618-623

John Wiley & Sons Inc

Access to resources Recommend Favorite

Anti-Angiogenic Effect of Bortezomib in Patients with Multiple Myeloma

By  

Acta Haematologica, Vol. 114, Iss. 3, 2005-10 ,pp. : 170-173

Karger

Access to resources Recommend Favorite